-continued

```
                470                 475                 480

Pro Trp Asp Gln Leu Phe Arg Asn Pro His Gln Ala Leu Leu His
                485                 490                 495

Thr Ala Asn Arg Pro Glu Asp Glu Cys Val Gly Glu Gly Leu Ala
                500                 505                 510

Cys His Gln Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly Pro
                515                 520                 525

Thr Gln Cys Val Asn Cys Ser Gln Phe Leu Arg Gly Gln Glu Cys
                530                 535                 540

Val Glu Glu Cys Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr Val
                545                 550                 555

Asn Ala Arg His Cys Leu Pro Cys His Pro Glu Cys Gln Pro Gln
                560                 565                 570

Asn Gly Ser Val Thr Cys Phe Gly Pro Glu Ala Asp Gln Cys Val
                575                 580                 585

Ala Cys Ala His Tyr Lys Asp Pro Pro Phe Cys Val Ala Arg Cys
                590                 595                 600

Pro Ser Gly Val Lys Pro Asp Leu Ser Tyr Met Pro Ile Trp Lys
                605                 610                 615

Phe Pro Asp Glu Glu Gly Ala Cys Gln Pro Cys Pro Ile Asn Cys
                620                 625                 630

Thr His Ser Cys Val Asp Leu Asp Asp Lys Gly Cys Pro Ala Glu
                635                 640                 645
```

What is claimed is:

1. A method of treating ErbB2-expressing breast cancer in a human, comprising administering to the human therapeutically effective amounts of (a) huMAb4D5-8 antibody; and (b) humanized 2C4 antibody variant 574.

2. The method of claim **1** wherein the huMAb4D5-8 antibody and the humanized 2C4 antibody are coadministered, using separate formulations or a single formulation.

3. The method of claim l wherein the huMAb4D5-8 antibody and the humanized 2C4 antibody are consecutively administered in either order.

4. The method of claim **3** wherein there is a time period during which both the huMAb4D5-8 antibody and the humanized 2C4 antibody simultaneously exert their biological activities.

5. A method of treating ErbB2-expressing breast cancer in a human, comprising administering to the human therapeutically effective amounts of (a) huMAb4D5-8 antibody; and (b) humanized 2C4 antibody comprising the variable light (V_L) domain amino acid sequence in SEQ ID NO:3, and the variable heavy (V_H) domain amino acid sequence in SEQ ID NO:4.

6. The method of claim **5** wherein the huMAb4D5-8 antibody and the humanized 2C4 antibody are coadministered, using separate formulations or a single formulation.

7. The method of claim **5** wherein the huMAb4D5-8 antibody and the humanized 2C4 antibody are consecutively administered in either order.

8. The method of claim **7** wherein there is a time period during which both the huMAb4D5-8 antibody and the humanized 2C4 antibody simultaneously exert their biological activities.

9. The method of claim **5** wherein the humanized 2C4 antibody is an intact IgG1 antibody.

* * * * *